Lilly's EBGLYSS (Lebrikizumab-Lbkz) Is The First And Only Selective Il-13 Inhibitor To Deliver Positive Phase 3 Outcomes In Patients Aged Six Months To 18 Years With Moderate-To-Severe Atopic Dermatitis

March 16 (Reuters) - Eli Lilly and Co LLY.N:

• LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) IS THE FIRST AND ONLY SELECTIVE IL-13 INHIBITOR TO DELIVER POSITIVE PHASE 3 OUTCOMES IN PATIENTS AGED SIX MONTHS TO 18 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

• ELI LILLY - ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EBGLYSS IN PEDIATRIC ATOPIC DERMATITIS

• ELI LILLY - IN PHASE 3, 63% ACHIEVED EASI-75 AND 44% ACHIEVED IGA 0,1 AT WEEK 16

• ELI LILLY - EBGLYSS SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES; NO INJECTION SITE PAIN REPORTED

• ELI LILLY - TO SUBMIT DATA FOR POTENTIAL LABEL UPDATE TO U.S. AND GLOBAL REGULATORS